News

The national nonprofit organization CureDuchenne and biotechnology company Prosensa Holding, both of which are committed to finding a cure for Duchenne muscular dystrophy (DMD) in different ways, recently presented a collaborative project at the 6th annual Partnering for Cures event. The conference, which is wrapping up today in New York City, gathered about 1,000…

Researchers throughout the world continue to work towards improved treatments for Duchenne muscular dystrophy (DMD). In response to recent advancements in the lab, the Muscular Dystrophy Association has published their Fall 2014 drug development update, highlighting the most prominent and promising DMD research and drug development. Translarna (ataluren),…

A study entitled “Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients” describes the positive results of using a recombinant adeno-associated virus vector to restore dystrophin levels in dogs affected with Duchenne muscular dystrophy.

Biopharmaceutical company Sarepta Therapeutics, which specializes in developing therapies for rare and infectious diseases, has been waiting for approval from the U.S. Food and Drug Administration (FDA) for its new drug treatment for muscular dystrophy. However, the FDA has decided to delay the decision, and has asked the company for more research. The FDA…

A group of investigators from the Massachusetts Institute of Technology (MIT) recently joined forces with the Myotonic Dystrophy Foundation (MDF) and Parent Project Muscular Dystrophy (PPMD) to host the second annual “Strength, Science, & Stories of Inspiration” event, which took place last Friday, November 7 at the MIT Museum in…

Almost $800,000 in funding was recently awarded to Murdoch University researchers from the Centre for Comparative Genomics (CCG) to develop genetic drugs to treat rare diseases. The money comes from the National Health and Medical Research Council (NHMRC) and will allow for the expansion of successful research into Duchenne Muscular Dystrophy…

Investigators from the Helmholtz Zentrum München and Ludwig-Maximilians-Universität München in Germany are organizing a crowd sourcing exercise as a way of determining new algorithms that they expect will be able to accelerate their research into treatment for amyotrophic lateral sclerosis (ALS). The challenge itself, as well as the most effective algorithms found, were recently published…

A group of researchers from Richland, Washington-based Pacific Northwest National Laboratory recently conducted a study that made use of an ultrasound technique that could be synced with smartphones to allow muscular dystrophy patients to monitor their response to medication. Michael S. Hughes is the lead investigator on the research…

The Italian Government recently approved the protein restoration therapy Translarna (ataluren) for the treatment of Duchenne muscular dystrophy (DMD), and included it in its medication list for reimbursement by the Italian National Health System. The oral drug treatment, developed by biopharmaceutical company PTC Therapeutics, will now be available in…

A new study entitled “Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing” published in the Clinical Epigenetics journal designed an assay that identifies the epigenetic signature for both types of Facioscapulohumeral muscular dystrophy from a multiple collections of…